News
I-Mab (IMAB) stock in focus as the company agrees to buy Bridge Health to secure rights for CLDN18.2 antibody used in its cancer drug, givastomig. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback